<p>This phase Ib/II single-arm study evaluated atezolizumab + bevacizumab for patients with treatment-refractory metastatic HPV+ anal cancer. The primary endpoint was best overall response, and secondary endpoints included progression-free survival, overall survival, and safety/tolerability. Paired tissue biopsies were collected in patients before treatment and at the time of first restaging and analyzed for whole-exome sequencing, RNAseq (Bulk), and multiplex immunofluorescence. The overall response rate among 20 patients was 10%. WES and RNAseq data are provided here.</p>

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Anus Neoplasms study with RNA-Seq, SNP/CNV Genotypes (NGS) + 2 more data on dbGaP (1 participants)